vs
Side-by-side financial comparison of INTEGRA LIFESCIENCES HOLDINGS CORP (IART) and Tradeweb Markets Inc. (TW). Click either name above to swap in a different company.
Tradeweb Markets Inc. is the larger business by last-quarter revenue ($617.8M vs $434.9M, roughly 1.4× INTEGRA LIFESCIENCES HOLDINGS CORP). On growth, Tradeweb Markets Inc. posted the faster year-over-year revenue change (21.2% vs -1.7%). Tradeweb Markets Inc. produced more free cash flow last quarter ($2.0M vs $-5.4M). Over the past eight quarters, Tradeweb Markets Inc.'s revenue compounded faster (23.5% CAGR vs 8.6%).
Integra LifeSciences Holdings Corporation is a global medical device manufacturing company headquartered in Princeton, New Jersey. Founded in 1989, the company manufactures products for skin regeneration, neurosurgery, reconstructive and general surgery. Integra artificial skin became the first commercially reproducible skin tissue used to treat severe burns and other skin wounds.
Tradeweb Markets Inc., headquartered in New York City, operates electronic trading platforms primarily used by institutional investors to trade fixed income products, ETFs, and derivatives. It has over 3,000 customers including banks, asset managers, central banks, pension funds, and insurance companies. In 2024, 83% of the company's revenue was from transaction fees and commissions and 17% was from subscription fees. In 2024, 52% of revenue came from products related to rates, 27% of revenue...
IART vs TW — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $434.9M | $617.8M |
| Net Profit | — | $233.2M |
| Gross Margin | 50.8% | — |
| Operating Margin | 5.3% | 46.5% |
| Net Margin | — | 37.7% |
| Revenue YoY | -1.7% | 21.2% |
| Net Profit YoY | — | 38.5% |
| EPS (diluted) | $-0.03 | $0.96 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $617.8M | ||
| Q4 25 | $434.9M | $521.2M | ||
| Q3 25 | $402.1M | $508.6M | ||
| Q2 25 | $415.6M | $513.0M | ||
| Q1 25 | $382.7M | $509.7M | ||
| Q4 24 | $442.6M | $463.3M | ||
| Q3 24 | $380.8M | $448.9M | ||
| Q2 24 | $418.2M | $405.0M |
| Q1 26 | — | $233.2M | ||
| Q4 25 | — | $325.0M | ||
| Q3 25 | $-5.4M | $185.6M | ||
| Q2 25 | $-484.1M | $153.8M | ||
| Q1 25 | $-25.3M | $148.4M | ||
| Q4 24 | — | $142.2M | ||
| Q3 24 | $-10.7M | $113.9M | ||
| Q2 24 | $-12.4M | $119.2M |
| Q1 26 | — | — | ||
| Q4 25 | 50.8% | — | ||
| Q3 25 | 51.5% | — | ||
| Q2 25 | 50.4% | — | ||
| Q1 25 | 50.8% | — | ||
| Q4 24 | 56.3% | — | ||
| Q3 24 | 52.6% | — | ||
| Q2 24 | 54.0% | — |
| Q1 26 | — | 46.5% | ||
| Q4 25 | 5.3% | 42.4% | ||
| Q3 25 | 2.9% | 41.4% | ||
| Q2 25 | -123.4% | 39.0% | ||
| Q1 25 | -4.0% | 40.0% | ||
| Q4 24 | 8.0% | 40.7% | ||
| Q3 24 | -2.1% | 35.5% | ||
| Q2 24 | -0.7% | 40.1% |
| Q1 26 | — | 37.7% | ||
| Q4 25 | — | 62.4% | ||
| Q3 25 | -1.3% | 36.5% | ||
| Q2 25 | -116.5% | 30.0% | ||
| Q1 25 | -6.6% | 29.1% | ||
| Q4 24 | — | 30.7% | ||
| Q3 24 | -2.8% | 25.4% | ||
| Q2 24 | -3.0% | 29.4% |
| Q1 26 | — | $0.96 | ||
| Q4 25 | $-0.03 | $1.52 | ||
| Q3 25 | $-0.07 | $0.86 | ||
| Q2 25 | $-6.31 | $0.71 | ||
| Q1 25 | $-0.33 | $0.69 | ||
| Q4 24 | $0.25 | $0.66 | ||
| Q3 24 | $-0.14 | $0.53 | ||
| Q2 24 | $-0.16 | $0.55 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $263.7M | — |
| Total DebtLower is stronger | $726.6M | — |
| Stockholders' EquityBook value | $1.0B | — |
| Total Assets | $3.6B | — |
| Debt / EquityLower = less leverage | 0.70× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $263.7M | $2.1B | ||
| Q3 25 | $267.9M | $1.9B | ||
| Q2 25 | $253.6M | $1.6B | ||
| Q1 25 | $273.3M | $1.3B | ||
| Q4 24 | $273.6M | $1.3B | ||
| Q3 24 | $277.6M | $1.2B | ||
| Q2 24 | $296.9M | $1.7B |
| Q1 26 | — | — | ||
| Q4 25 | $726.6M | — | ||
| Q3 25 | $736.3M | — | ||
| Q2 25 | $745.9M | — | ||
| Q1 25 | $755.6M | — | ||
| Q4 24 | $760.5M | — | ||
| Q3 24 | $765.3M | — | ||
| Q2 24 | $770.2M | — |
| Q1 26 | — | — | ||
| Q4 25 | $1.0B | $6.5B | ||
| Q3 25 | $1.0B | $6.3B | ||
| Q2 25 | $1.0B | $6.1B | ||
| Q1 25 | $1.5B | $5.9B | ||
| Q4 24 | $1.5B | $5.8B | ||
| Q3 24 | $1.5B | $5.7B | ||
| Q2 24 | $1.5B | $5.6B |
| Q1 26 | — | — | ||
| Q4 25 | $3.6B | $8.2B | ||
| Q3 25 | $3.6B | $8.0B | ||
| Q2 25 | $3.7B | $8.1B | ||
| Q1 25 | $4.1B | $7.4B | ||
| Q4 24 | $4.0B | $7.3B | ||
| Q3 24 | $4.1B | $7.3B | ||
| Q2 24 | $4.1B | $7.3B |
| Q1 26 | — | — | ||
| Q4 25 | 0.70× | — | ||
| Q3 25 | 0.71× | — | ||
| Q2 25 | 0.72× | — | ||
| Q1 25 | 0.50× | — | ||
| Q4 24 | 0.49× | — | ||
| Q3 24 | 0.50× | — | ||
| Q2 24 | 0.50× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $11.8M | — |
| Free Cash FlowOCF − Capex | $-5.4M | $2.0M |
| FCF MarginFCF / Revenue | -1.2% | 0.3% |
| Capex IntensityCapex / Revenue | 4.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-31.1M | $1.1B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $11.8M | $355.9M | ||
| Q3 25 | $40.9M | $342.3M | ||
| Q2 25 | $8.9M | $409.2M | ||
| Q1 25 | $-11.3M | $60.2M | ||
| Q4 24 | $50.7M | $282.0M | ||
| Q3 24 | $22.5M | $292.1M | ||
| Q2 24 | $40.4M | $285.7M |
| Q1 26 | — | $2.0M | ||
| Q4 25 | $-5.4M | $336.5M | ||
| Q3 25 | $25.8M | $328.3M | ||
| Q2 25 | $-11.2M | $403.7M | ||
| Q1 25 | $-40.2M | $58.6M | ||
| Q4 24 | $21.1M | $256.8M | ||
| Q3 24 | $-7.2M | $287.8M | ||
| Q2 24 | $10.7M | $280.8M |
| Q1 26 | — | 0.3% | ||
| Q4 25 | -1.2% | 64.6% | ||
| Q3 25 | 6.4% | 64.5% | ||
| Q2 25 | -2.7% | 78.7% | ||
| Q1 25 | -10.5% | 11.5% | ||
| Q4 24 | 4.8% | 55.4% | ||
| Q3 24 | -1.9% | 64.1% | ||
| Q2 24 | 2.6% | 69.4% |
| Q1 26 | — | — | ||
| Q4 25 | 4.0% | 3.7% | ||
| Q3 25 | 3.8% | 2.8% | ||
| Q2 25 | 4.8% | 1.1% | ||
| Q1 25 | 7.6% | 0.3% | ||
| Q4 24 | 6.7% | 5.4% | ||
| Q3 24 | 7.8% | 1.0% | ||
| Q2 24 | 7.1% | 1.2% |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.10× | ||
| Q3 25 | — | 1.84× | ||
| Q2 25 | — | 2.66× | ||
| Q1 25 | — | 0.41× | ||
| Q4 24 | — | 1.98× | ||
| Q3 24 | — | 2.56× | ||
| Q2 24 | — | 2.40× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IART
| Neurosurgery | $226.2M | 52% |
| Asia Pacific | $53.7M | 12% |
| Instruments | $52.3M | 12% |
| ENT | $44.8M | 10% |
| Other | $38.9M | 9% |
| Rest Of The World | $19.0M | 4% |
TW
| Transaction fees and commissions | $523.8M | 85% |
| Subscription fees | $60.3M | 10% |
| LSEG market data fees | $26.7M | 4% |
